ClinicalTrials.gg
CompletedNCT04525820VitCovUpdated Feb 8, 2023

High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study

An interventional study of Single high dose vitamin D and Placebo in Covid19, Vitamin D Deficiency and Corona Virus Infection, sponsored by Prof. Dr. Jörg Leuppi. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Prof. Dr. Jörg Leuppi · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.

Enrollment
28th of 49
80 · median 100
Started
2020
with 47 others
No phase
16 of 97
3 open now
Registered
40th of 97
by date
Lead sponsor
2 of 97
Prof. Dr. Jörg Leuppi

Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 28th largest by enrollment of the 49 interventional ones that give a count, is one of 48 that started in 2020, is one of 16 with no phase, and was the 40th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in COVID-19 with a site in Switzerland, or all of them as a file.
02

Study summary

The world is currently facing a pandemic with the coronavirus (SARS-CoV-2) which leads to the disease of COVID-19. Risk factors for a poor outcome of COVID-19 have so far been identified as older age and co-morbidity including chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) and current smoking status. Previous studies found, that vitamin D deficiency is more prevalent among patients with these risk factors. There are observational studies reporting independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating vitamin D metabolite) and susceptibility to acute respiratory tract infection.

Vitamin D substitution in patients with COVID-19 who show a vitamin D deficiency should therefore be investigated for efficacy and safety.

The study is designed as a randomized, placebo-controlled, double blind study. The objective of the study is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 treated under standardized conditions in hospital will recover faster when additionally treated with a single high dose of vitamin D compared to standard treatment only.

Read the detailed description

The world is currently experiencing a coronavirus (SARS-CoV-2) pandemic. The disease caused by infection with this virus is known as COVID-19. Risk factors for a poor outcome of COVID-19 have so far been found to include, older age and co-morbidity including chronic respiratory conditions and current smoking status. Previous studies found, that vitamin D deficiency is more prevalent among patients with these risk factors.

There are observational studies reporting independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating vitamin D metabolite) and susceptibility to acute respiratory tract infection. 25-hydroxyvitamin D supports induction of antimicrobial peptides in response to both viral and bacterial stimuli suggesting a potential mechanism by which vitamin D inducible protection against respiratory pathogens might be mediated. The clear functions of vitamin D in the immune system are difficult to define because the immune response is not a static process. The vitamin-D-receptor, which has also been detected in immunological cells, suggests that vitamin D can regulate some processes related to immunity. A further argument which supports a potential antiviral activity of vitamin D is the modulation of the inflammatory response. The release of pro-inflammatory cytokines by the influenza virus appeared to correlate with the severity of illness. The use of vitamin D as a prophylactic for influenza has shown promise in prevention of illness and reduction of secondary asthma in children. Inadequate vitamin D status is associated with susceptibility to upper respiratory infections in patients with chronic obstructive pulmonary disease (COPD). In the ViDiCo-trial vitamin D supplementation protected against moderate or severe exacerbation, but not upper respiratory infection, in patients with COPD. A further study retrospectively examined data from 108 patients with acute respiratory distress syndrome (ARDS) for whom a vitamin D status was available at the time of diagnosis revealed that over 95% of these patients had vitamin D deficiency. When examined according to quarterly of serum 25- hydroxyvitamin D, a consistent inverse relationship between serum 25-hydroxyvitamin D and length of hospital and ICU stay among survivors was observed. Vitamin D substitution in patients with COVID-19 who show a vitamin D deficiency should therefore be investigated for efficacy and safety.

For this purpose the investigators designed a randomized, placebo controlled double blind trial to test the hypothesis hypothesis that a single high dose of vitamin D in addition to standard treatment improves the recovery period positively in patients with COVID-19 and vitamin D deficiency compared to standard treatment only. That means, that the time of recovery is shorter in the single high dose vitamin D group relative to standard treatment group only.

03

Conditions studied

  • Covid19
  • Vitamin D Deficiency
  • Corona Virus Infection
  • ARDS
  • Coronavirus
  • SARS-CoV Infection

Keywords

  • Covid19
  • Vitamin D Deficiency
  • ARDS
  • Corona Virus
  • High dose vitamin D
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Hospitalized Patient
  • Ongoing COVID-19 infection
  • Vitamin D deficiency defined as a serum 25-hydroxyvitamin D concentration ≤ 50nmol/l( ≤20ng/ml)
  • > 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Known to one of the used products of vitamin D or indigents in the drug's composition
  • Active
  • Hypercalcemia
  • Granulomatous disease such as sarcoidosis
  • History of renal stones within the past year
  • Pregnancy/breastfeeding, as evaluated through screening,
  • Previous enrollment into the current study,
  • Enrollment of the investigator, his/her family members, employees and other dependent persons,
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    High Dose Vitamin D

    Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D. The medication be administered orally

    Drug: Single high dose vitamin D · Drug: Treatment as usual vitamin D

  • Placebo comparator
    Placebo

    Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)

    Drug: Placebo · Drug: Treatment as usual vitamin D

Interventions

  • DrugSingle high dose vitamin D

    Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU

    Also known as: VITAMIN D3 oil 500 IU/drop

  • DrugPlacebo

    Patient receives a single dose of a placebo solution

    Also known as: Oily placebo solution

  • DrugTreatment as usual vitamin D

    Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day

    Also known as: Vitamin D3 solution 4000 IU/ml

06

What researchers measure

Primary outcomes

  1. Length of hospitalization

    Overall duration of the hospitalization from day of admission until the day of discharge or fatality

    Time frame: Administration to Discharge from hospital care (mean duration is between 14 and 22 days for Patients with COVID 19)

Secondary outcomes

  1. Need of intensive care

    Did the patient need a intensive care treatment during the hospitalization (yes/no)

    Time frame: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

  2. Lenght of the Intensive Care Treatment

    Day of admission to ICU until discharge or fatality

    Time frame: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

  3. Overall mortality

    Percentage of patient died during hospitalization

    Time frame: During the length of hospitalisation (mean duration is between 14 and 22 days for Patients with COVID-19)

  4. Development of vitamin D levels

    percentage of patients with 25-hydroxyvitamin D \> 50nmol/L (\>20ng/mL) at day 7 - The values of calcium, phosphorus, 24-hydroxyvitamin D, 1.25-dihydroxyvitamin D, parathyroid hormone.

    Time frame: Day 1 (Baseline) and Day 7 after the first administration of the high dose vitamin D or the placebo and at discharge (mean hospital stay is between 14 and 22 days for Patients with COVID-19)

  5. Development of sepsis

    percentage of patients developing a sepsis

    Time frame: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)

Other outcomes

  1. Complications due to COVID-19

    We assess every other complications which occurs due to COVID-19

    Time frame: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)

  2. Blood pressure (BP)

    The BP will be assessed daily in mmHg

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

  3. Heart rate

    The heart rate will be assessed daily in bpm

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)

  4. Peripheral oxygen saturation (SpO2)

    The SpO2 will be assessed daily in %

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

  5. Percentage of patients who require oxygen

    Requirement for oxygen will be assessed daily (yes/no) if yes how many liters per minute

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

  6. Breathing frequency

    Breathing frequence will be assessed daily in breaths per minute

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

  7. Glasgow Coma Scale (GCS)

    GCS will be assessed daily 3 to 15 points. It describes the extent of impaired consciousness. 15 points means no impairment, 3 points means severe impairment of consciousness.

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

  8. Percentage of patients are smokers, former smokers or lifelong non-smokers

    Assessing the history of smoking in pack years (PY). the assessment will be made with the following options for answering Current smoker: Smoking for how many years? Cigarettes per day? Former smoker, how many years smoked? How many cigarettes per day Life-long non-smoker

    Time frame: Assessing of the smoking Status at Basleine

  9. Current Symptoms

    Assessed in No/ Mild/ Moderate /Severe

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

  10. Temperature

    Temperature will be assessed daily in degrees celsius

    Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)

07

Study locations

2 sites
  • Cantonal Hospital Baselland Liestal
    Liestal, BL 4410, Switzerland
  • Cantonal Hospital St. Gallen
    Saint Gallen, SG 9001, Switzerland
08

References and documents

Publications

  • Jaun F, Boesing M, Luthi-Corridori G, Abig K, Makhdoomi A, Bloch N, Lins C, Raess A, Grillmayr V, Haas P, Schuetz P, Gabutti L, Muser J, Leuppi-Taegtmeyer AB, Giezendanner S, Brandle M, Leuppi JD. High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study-VitCov Trial. Trials. 2022 Feb 4;23(1):114. doi: 10.1186/s13063-022-06016-2. PubMed 35120577 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Aug 2021, 8 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Aug 25, 2020
StartActual
Dec 15, 2020
Primary completionActual
Aug 30, 2021
CompletionActual
Nov 30, 2021
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04525820
Lead sponsor
Prof. Dr. Jörg Leuppi
Responsible party
Prof. Dr. Jörg Leuppi (Chief Physician, Medical University Clinic, Principal Investigator, Cantonal Hosptal, Baselland) — Sponsor-investigator
First posted
Aug 25, 2020
Start date
Dec 15, 2020
Primary completion
Aug 30, 2021
Completion
Nov 30, 2021
Last update
Feb 8, 2023

Study contacts

Jörg D Leuppi, Professor
study director · Cantonal Hosptal, Baselland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion